Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A-dmDT390-anti-CD3 immunotoxin

Drug Profile

A-dmDT390-anti-CD3 immunotoxin

Alternative Names: A-dmDT390-bisFv; A-dmDT390-bisFv(UCHT1); Anti-CD3 antibody-diphtheria toxin conjugate; Anti-CD3 bivalent antibody-diphtheria toxin conjugate; LAX-699; Recombinant anti-CDR-bi-single-chain-Fv-diptheria toxin fusion protein; Resimmune; UCHT-1-Angimmune

Latest Information Update: 20 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Angimmune; University of Louisville
  • Class Drug conjugates; Immunotoxins; Peptides
  • Mechanism of Action Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cutaneous T-cell lymphoma; Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Angimmune plans a phase I/II trial for Melanoma (late-stage disease; Adjunctive therapy) in USA (NCT02990416)
  • 30 Nov 2016 Angimmune completes a phase II trial in Cutaneous T-cell lymphoma in USA (NCT00611208)
  • 22 Nov 2016 Angimmune terminates a phase-I/II clinical trial in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT01888081)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top